Premium
Characteristics and prognostic significance of incidentally detected cancer cells in uterine specimens of patients with pelvic high‐grade serous carcinoma
Author(s) -
Ushigusa Takeshi,
Yoshida Hiroshi,
Kuno Ikumi,
Kojima Naoki,
Ishikawa Mitsuya,
Kato Tomoyasu
Publication year - 2020
Publication title -
cytopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.512
H-Index - 48
eISSN - 1365-2303
pISSN - 0956-5507
DOI - 10.1111/cyt.12796
Subject(s) - medicine , serous fluid , serous carcinoma , uterine cancer , biopsy , carcinoma , cytology , stage (stratigraphy) , serous membrane , ascites , endometrial cancer , ovarian cancer , gynecology , cancer , pathology , paleontology , biology
Objective Cases of pelvic high‐grade serous carcinoma ( HGSC ) with incidentally detected cancer cells ( ICC s) in endometrial and/or cervicovaginal cytology have been reported. This study aimed to clarify the incidence and characteristics of pelvic HGSC with ICC s and to determine whether ICC s have a negative prognostic impact. Methods Patients with ovarian/tubal/peritoneal HGSC who underwent pre‐treatment uterine (endometrial/cervicovaginal) cytology or biopsy between January 2007 and May 2017 were included. We reviewed the frequencies of ICC s and compared the clinicopathological features and survival outcome between the ICC ‐positive and ICC ‐negative groups. Results Of the 160 patients evaluated, 69 (43.2%) had positive ICC s in at least one uterine specimen. There were no significant differences in clinicopathological characteristics, such as age, FIGO stage, serum CA 125 level, ascites, and tubal lesion, between the two groups. Moreover, ICC s had no significant survival impact on progression‐free survival or overall survival. Conclusion Our study showed a high rate of pelvic HGSC with ICC s in pre‐treatment uterine specimens. The ICC s per se had no negative impact on survival outcomes of pelvic HGSC . Furthermore, uterine biopsy and cytology can be useful and less‐invasive methods to obtain tubo‐ovarian/peritoneal cancer cells before treatment.